Exclusive Summary

• Unprecedented VHH Structure & Miniaturized Size: It is the first PD-L1/VEGF bispecific antibody built with VHH domains, yielding an ultra-small molecular weight of 105 kDa that ensures superior penetration into solid tumor tissues.
• Compelling Best-in-Class Efficacy: Extensive in vitro and in vivo models confirm that UB023 significantly outperforms approved mAbs like Atezolizumab and leading BsAb benchmarks (AK112, IMM-2510) in target blocking and tumor growth inhibition.
• Breakthrough CMC and Stability Profile: UB023 overcomes the structural degradation and aggregation issues plaguing heavier competing bispecifics, boasting a 100% monomer purity post-Pro-A purification and a highly viable GMP cell line titer of 4 g/L.
• De-risked and Highly Lucrative Partnering Potential: As the PD-L1 x VEGF mechanism has recently triggered massive multi-billion-dollar global out-licensing deals for lung and breast cancer indications, UB023 offers a flawless 'next-generation' asset for MNCs seeking to capture this booming market.

Asset Materials

Contact Us for Full Materials